Companies · ABCL · Pharmaceutical Preparations

AbCellera Biologics Inc. (ABCL)

Every material event, decoded in plain English — what each one means for the stock.

Aug 13, 2026$200M equity offering

Strong trial data, then a $200M dilution deal

ABCL635 delivers a strong Phase 2 efficacy readout, exceeding the bar

Phase 2 ABCL635 data arrives Monday; no clinical result yet

Open live on AllSight — the whole market, decoded →